Nuvectis Pharma NVCT 深 沪
等待开盘 11-06 09:30:00 美东时间
17.76
-0.710
-3.84%
华盛通- 最 高18.525
- 今 开18.15
- 成交量 34.01万股
- 最 低 17.24
- 昨 收 18.47
- 总市值 5.80亿
- 52周最高 29.275
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.77
- 委 比 87.85%
- 总股本 3264.41万
- 历史最高 29.275
- 量 比 1.67
- 振 幅 6.96%
- 历史最低 3.08
- 每 手 1
- 风险率 6.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nuvectis Pharma Q3 EPS $(1.02) Misses $(0.24) Estimate
Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(1.02) per share which missed the analyst consensus estimate of $(0.24) by 325 percent. This is a 131.82 percent decrease over losses of $(0.44) per share from the same period last year.
11-04 20:11
Nuvectis Pharma收涨3.79%，成交额401.93万美元
11月3日，Nuvectis Pharma（NVCT）收涨3.79%，报19.18美元，成交额401.93万美元，市值6.26亿美元。 行情数据 • 开盘价：...
11-03 06:58
Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026
Nuvectis Pharma, Inc. (NASDAQ: NVCT) announced it will host a conference call and webcast on November 4, 2026, at 8:00 AM ET to discuss third-quarter 2026 business progress and financial results. The call can be accessed via dial-in numbers (U.S.: 1-877-407-0752; International: 1-201-389-0912) using conference ID 13763643 or via webcast [here](https://www.globenewswire.com/Tracker?data=oLY_ByEMgM6oWGVJ_Ei9IjDlDWYwpHpZaPYaxybjWd54lXjov5pcke-iMqbL9...
11-02 22:00
Nuvectis Pharma收跌7.78%，成交额590.29万美元
10月27日，Nuvectis Pharma（NVCT）收跌7.78%，报18.49美元，成交额590.29万美元，市值6.04亿美元。 行情数据 • 开盘价...
10-27 06:01
Nuvectis Pharma Reports Data From Its Phase 1b Trial Of NXP200 Demonstrates Objective Response Rate Based On Response Assessment In Neuro-Oncology Criteria 2.0 Of 40%; Deep Responses Were 87.5%
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today provided highlights from the oral presentation of positive, expande...
10-26 20:34
Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
Nuvectis Pharma reported positive Phase 1b data for NXP200, a second-generation BRAF inhibitor, in patients with recurrent or progressive BRAF V600-mutated gliomas. The study included 27 patients, with an objective response rate (ORR) of 40% in high-grade glioma and 42.9% in low-grade glioma. Deep responses (>80% tumor reduction) were observed in 87.5% of high-grade and 66.7% of low-grade responders. NXP200 demonstrated a manageable safety profil...
10-26 12:30
Nuvectis Pharma收跌1.74%，成交额292.42万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:02
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
Nuvectis Pharma, Inc. announced that its senior management will participate in the Maxim Growth Summit 2026 on October 14, 2026, in New York. Ron Bentsur, Chairman and CEO, will present at a panel discussion on Immunology & Inflammation Therapies. The event will be webcast and available on the company's website. Nuvectis focuses on developing therapies for complement-related conditions and oncology, with key drug candidates including ciprocopan, ...
10-09 12:00
美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $39 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $39 price target.
09-24 22:32
